FDA Clears Neurotronics Sleep Analysis Module for Home Sleep Testing

The US Food and Drug Administration has granted 510(k) clearance to Neurotronics' Sleep Analysis Module (SAM), the company's first FDA-cleared AI/ML-based sleep analysis device, according to the agency's clearance database record K261521. The clearance, announced by Neurotronics, a Nihon Kohden company, covers a software-only medical device that estimates total sleep time (TST) from a signal most home sleep tests already collect.

SAM analyzes the photoplethysmography (PPG) signal generated by a standard pulse oximeter. No additional sensor is required, and the patient setup does not change. The module will initially integrate into Neurotronics' Polysmith sleep diagnostic software for analysis of studies recorded with the NomadAir home sleep apnea testing solution.

Why total sleep time matters for apnea scoring

The clinical problem SAM targets sits at the center of home sleep testing workflows. In sleep apnea assessment, respiratory events are evaluated relative to the amount of time a patient is actually asleep. But measuring sleep itself has traditionally required additional signals: electroencephalography, electrooculography, and electromyography — channels that home tests rarely capture.

As a result, many home sleep studies substitute total recording time for total sleep time. That substitution can inflate the denominator. Periods when the patient lies awake in bed enter the calculation, which can affect the apnea-hypopnea index and, with it, the evaluation of obstructive sleep apnea severity. SAM addresses this gap by estimating TST from the PPG data the pulse oximeter already acquires, giving clinicians an estimate that more closely reflects the patient's actual sleep duration.

What the clearance establishes

Neurotronics frames the FDA decision as three milestones:

• First AI/ML-based clearance. SAM is the company's first FDA-cleared AI/ML sleep analysis device and, the company says, provides a pathway for future AI/ML medical device development.
• New information from an existing signal. The module extracts clinical information from PPG data already being collected, with no added hardware.
• A software-only footprint. Because SAM is software, Neurotronics sees opportunities to extend advanced sleep analysis across compatible products and platforms that acquire appropriate PPG signals.

Jake Johnson, president and CEO of Neurotronics, LLC, said in a release: "FDA clearance of the Sleep Analysis Module is a defining milestone for Neurotronics. SAM demonstrates how validated software can provide new clinical information from physiological signals already being collected, without requiring additional hardware."

Johnson added that the achievement "reflects years of collaboration across engineering, clinical validation, quality, and regulatory disciplines and establishes a foundation for continued innovation in software-driven medical technology."

What the labeling restricts

The clearance carries limits that sleep program managers should note before changing protocols. SAM is a prescription-only device, intended for use by or under the supervision of a clinician, to aid in the diagnosis of sleep disorders in patients 18 years of age and older. The FDA label states it is not intended for use when full sleep staging signals are available — in-lab polysomnography remains the reference path — and it is not intended to serve as the sole or primary basis for diagnosing any sleep disorder.

For R&D and portfolio teams in sleep diagnostics, the clearance signals where the market is moving: incremental clinical value extracted from signals already in the recording chain, delivered as software rather than new sensors. Neurotronics has not disclosed a commercial release date for the Polysmith integration, nor published performance metrics for the TST estimation algorithm; both will determine how quickly labs can act on the claim.